Skip to main content
Sign In

University of Colorado Denver Hematology, Blood Cancer, Bone Marrow Transplant Program

 Blood Cancer, Bone Marrow Transplant Program Logo
 

Clinical Trials

​See what human subject trials are accepting applicants


For more information click the study identifier or search the identifier number at clinicaltrials.gov.

 Acute Lymphoblastic Leukemia (non transplant)

ClinicalTrials.gov
Identifier
Study Title ​Study Coordinator
NCT01132573 A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease​ ​Nicole Adler, 720-848-0678
​​1

 Acute Myeloid Leukemia (non-transplant)

 
ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. Greg Hemenway, 720-848-8026

NCT02335814​​

​Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia. Greg Hemenway, 720-848-8026​
​NCT02203773 ​A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. ​Sejal Tailor, 720-848-3773​

NCT02074839​​

​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation. ​Sejal Tailor,  720-848-3773
NCT00840177 ​S0919, A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) Emily Denoncourt, 720-848-0566

​​​​​​​​​​​10

 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01886859 A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ​Nicole Adler, 720-848-0678

NCT02475681

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

Greg Hemenway, 720-848-8026

​​2

 Hodgkin Lymphoma (non transplant)

No current trials recruiting3

 Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
​NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. Greg Hemenway, 720-848-8026
NCT02074839 ​A Phase I, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation.

​Sejal Tailor, 720-848-3773​

​​​​​​​4

 Myeloma (non transplant)

ClinicalTrials.gov Identifier Study Title Study Coordinator
NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. ​Greg Hemenway, 720-848-8026
​​5

 Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​6

 Non Hodgkin Lymphoma: Mantle Cell (non transplant)

​No current trials recruiting7

 Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
​NCT02492737​ ​A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. ​Greg Hemenway, 720-848-8026
NCT02257567​ ​A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. ​Emily Denoncourt, 720-848-0566
​​​​8

 Transplant

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator​
​NCT01841333 ​A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ​​Emily Denoncourt,
720-848-0566
​​9